PRESS RELEASE

Ergomed to present at the German Equity Forum 2017

London, UK - 27 November 2017:Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces its attendance at the German Equity Forum 2017 (Deutsches Eigenkapitalforum) which will be taking place at The Sheraton Frankfurt Airport Hotel & Conference Center in Frankfurt am Main, Germany, from 27 to 29 November.

Dr. Miroslav Reljanovic, Executive Vice-Chairman, will be presenting at 11:00am CET on 27 November.

ENDS

Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Executive Vice Chairman)

Stephen Stamp (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit:http://ergomedplc.com.

Ergomed plc published this content on 27 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 November 2017 07:11:11 UTC.

Original documenthttp://otp.investis.com/clients/uk/ergomed/rns/regulatory-story.aspx?cid=1407&newsid=952971

Public permalinkhttp://www.publicnow.com/view/D44B5D48CD38B0B531DB588DB22FFC99D7D05E49